Zai Lab Limited (HKG:9688)
14.48
+0.85 (6.24%)
At close: Dec 24, 2025
Zai Lab Revenue
Zai Lab had revenue of $116.10M USD in the quarter ending September 30, 2025, with 13.52% growth. This brings the company's revenue in the last twelve months to $441.63M, up 24.14% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$441.63M
Revenue Growth
+24.14%
P/S Ratio
4.68
Revenue / Employee
$236.29K
Employees
1,869
Market Cap
16.07B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
Zai Lab News
- 1 day ago - Zai Lab Receives Approval In China For Schizophrenia Drug COBENFY - Nasdaq
- 2 days ago - Zai Lab Secures China's Approval For Schizophrenia Therapy In Adults - Nasdaq
- 2 days ago - Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
- 6 days ago - Insider Sell: Edmondson Frazor Titus III Sells 8,651 Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 17 days ago - Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire
- 18 days ago - Zai Lab (ZLAB) Secures Renewal for Key Drugs in China's 2025 NRDL - GuruFocus
- 18 days ago - Zai Lab Announces Updates to China's National Reimbursement Drug List - Business Wire
- 5 weeks ago - Wellington Management Group LLP's Strategic Acquisition in Zai Lab Ltd - GuruFocus